Crohn Disease and Comorbid T2D May Lead to More Severe Disease, Undertreatment

['.Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow', 'Class', 'Wp-Block-Co-Authors-Plus', 'Display Inline', '.Wp-Block-Co-Authors-Plus-Avatar', 'Where Img', 'Height Auto Max-Width', 'Vertical-Align Bottom .Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow .Wp-Block-Co-Authors-Plus-Avatar', 'Vertical-Align Middle .Wp-Block-Co-Authors-Plus-Avatar Is .Alignleft .Alignright', 'Display Table .Wp-Block-Co-Authors-Plus-Avatar.Aligncenter Display Table Margin-Inline Auto'] News Archive - Endocrinology Advisor 2025-09-24 05:10:07

The probability of remaining corticosteroid-free at 5 years was 31.5% in the CD plus T2D group vs 38.5% in the CD-only group. At 5 years, the probability to be free of drug-related events was 94.2% in the CD plus T2D group vs 97.6% in the CD-only group. In the follow-up, 749 individuals in the CD plus T2D group (10.4%) received anti-tumor necrosis factor therapy vs 878 in the CD-only group (12.2%), and 330 in the CD plus T2D group (4.6%) received interleukin-23 inhibitors vs 387 in the CD-only group (5.4%). Neoplasms occurred in 3.5% of individuals in the CD plus T2D group and 3.2% in the CD-only group. Also, 51.5% of patients in the CD plus T2D group had at least 1 mental, behavioral, or neurodevelopmental disorder diagnosis vs 41.2% in the CD-only group.